Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
There was a conflicting study which indicated that NSAIDS were associated with increased the rick of death, so I find this interesting but not convincing.
I have noted over the past year or two the large institutional ownership of this stock but the current levels surprise even me. Thanks for the link.
Good luck!
-Fritz
I haven't checked in here in a while. Who was locked up?
Thanks,
-Fritz
Today's move is all the more notable because it is in opposition to the down draft from the IBB and XBI. Volume continues to impress.
Yes, you called it! Impressive volume in the first 30 minutes of trading.
Looks like the next leg up has started.
Nice move back up near all time highs on pretty good volume.
RVNC Needham Maintains Buy Raises Price Target to $42
https://www.benzinga.com/news/20/10/17916832/needham-maintains-buy-on-revance-therapeutics-raises-price-target-to-42
Thanks for the update, maumar.
Good stuff, thanks!
I think a buyout would cost upwards of $10 Billion. Does Genmab have that kind of cash laying around?
I don't see it but the chart is getting close to oversold, IMHO.
Glad to hear she was upbeat. I'm in RVNC and they presented yesterday and today they are seeing a nice pop on large volume. Hopefully HALO follows suit tomorrow. Feels like there is merger mania in the air. Stay tuned. LOL!
It's go up with the next news item.
That's not accurate. My mistake. The PT is accurate but the previous PT was $23 per Benzinga
https://www.benzinga.com/stock/halo/ratings
According to my news feed they went from $14 to $28 on their price target. Very bold assertion! LOL!
That actually made me laugh out loud.
Ha! There was a dropped digit in the form which appeared in the "news" link here on the HALO board. Your form is probably correct and more significant. Looks like Helen sold some also, but hers was a gift to a charitable organization.
https://www.sec.gov/Archives/edgar/data/1159036/000117911020009047/xslF345X03/edgar.xml
Daly sold about 10% of his holdings.
Also could be a sector thing as both IBB and XBI are down today....
I am surprised Kirk had any remaining interest in HALO. I thought he had more or less liquidated last year.
exactly. self dealing corrupt management with no effective oversight. The definition of DPDW.
If Helen comes up with 2-3 new partnerships before year's end (and I have a suspicion she will) we'll easily make your target IMHO.
-Fritz
Spec, glad to hear from you and thanks for all of your posts back then. I took a beating as you said but it was, I realize now, tuition the school of hard knocks. I hope you are thriving in all arenas of life.
Best,
-Fritz
Also I'm noticing zero volume. There is no market for DPDW. Too many burned fingers. That's a biggie. You can check in any time you like but you can never leave. LOL!
This company has never been run for the benefit of shareholders; corporate governance rules were adopted long ago to ensure that the insiders benefit at the expense of individual investors. As far as I know those rules are still in place. Ron and his ilk created a corrupt corporate culture of self dealing and outright thievery and individual shareholders have no recourse under the corporate charter. One would be wise in not assuming that that has changed simply because Cap'n Ron has moved offstage. Run away and don't look back. There are plenty of other investing opportunities - why wade into a cesspool like DPDW?
Good luck!
-Fritz
She never gives a time frame, because that is out of her control and she is very reluctant to over-promise and risk under-delivering. But when she speaks about deals coming, you can bet that they are in the offing, and not too far off.
-Fritz
Thanks for pointing that out. She is not one to exaggerate in my estimation, so when she talks about coming deals and the atmosphere surrounding future prospects, it's best to take her literally. Stay tuned...
-Fritz
Absent any larger headwinds I'd say we'll start another leg up into the $30's within the next few days or early next week. Just speculating for fun but the upgrades were significant and there are probably a few more coming out soon. The chart is wound up pretty tight also.
Good luck!
-Fritz
Interesting, thanks! (EOM)
Nothing was said about covid per se but she virtually guaranteed a new deal and strongly implied there would be more than one.
She never does that unless it's imminent so stay tuned.
-Fritz
Pay wall. Can you insert any of the text here?
Just as a thought experiment, I wonder what the buyout pps would be using the same metrics. Someone who is good at actuarial math (not me) should chime in. Take as a given Helen's income projections that ramp up to $1 Billion by 2027 and what would be the present value of that income stream today assuming a 2% return on investment per annum?
Just looking at it as a quasi-dividend play. ..$.75 is a 2% return per annum on $36 per share.
The PR says they will make $.60-.75 per share this year. The higher number $.75, if achievable, puts fair value of the stock at $36 in my opinion. This would be a 2% return per annum.
-Fritz
It appears to me that the average premium to market has jumped to astronomical levels compared even to just a year ago. Am I off base here, Dew?
-Fritz
With the A/S raised, a clear path to triple zeros ahead.
Piper Sandler raises PT to $31.
https://www.thecerbatgem.com/2020/07/02/halozyme-therapeutics-nasdaqhalo-price-target-raised-to-31-00.html
Chart of current analyst price targets:
Date Research Firm Action Current PT
7/01/20 Benchmark Initiates Coverage On Buy 39.0
6/15/20 Citigroup Maintains Neutral 26.0
5/19/20 Canaccord Genuity Maintains Buy 27.0
5/12/20 JMP Securities Maintains Market Outperform 34.0
5/12/20 JP Morgan Maintains Overweight 23.0
5/12/20 BMO Capital Maintains Outperform 35.0
5/04/20 Cantor Fitzgerald Reiterates Overweight 39.0
2/25/20 Barclays Maintains Equal-Weight 20.0
2/25/20 JP Morgan Maintains Overweight 22.0
2/05/20 Piper Sandler Upgrades Overweight 27.0
Benchmark analyst Robert Wasserman initiates at PT of $39
https://www.benzinga.com/stock/halo/